IPCA Laboratories Quarterly Results
IPCA Laboratories quarterly results. In Sept 2026, IPCA Laboratories (IPCALAB) reported revenue ₹2,935 Cr and net profit ₹389 Cr — revenue +13.6% YoY. For annual financials, live price and key ratios, visit IPCA Laboratories share price today.
IPCALAB Quarterly Results — Revenue, Profit & EPS Highlights
IPCA Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View IPCA Laboratories yearly highs lows for the annual high/low range and current price position.
- Revenue of ₹2,935 Cr in Sept 2026 (+18.3% vs Mar 2026, +13.6% vs Sept 2025)
- Net Profit of ₹389 Cr in Sept 2026 (+26.7% vs Mar 2026, +38.4% vs Sept 2025)
- EBITDA of ₹674 Cr in Sept 2026 (+26.7% vs Mar 2026)
- Operating Margin of 22.0% in Sept 2026 (+4.0pp vs Mar 2026)
- Earnings Per Share of ₹14.79 in Sept 2026 (+11.1% vs Mar 2026)
IPCA Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
IPCALAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 2,935 | 2,482 | 2,813 | 2,584 | 2,273 | 18.3% | 13.6% |
| Net Profit (₹ Cr) | 389 | 307 | 424 | 281 | 64 | - | - |
| EBITDA (₹ Cr) | 674 | 532 | 695 | 515 | 250 | - | - |
| EPS (₹) | 14.79 | 13.31 | 15.84 | 11.14 | 2.67 | - | - |
| Operating Margin (%) | 22.0% | 18.0% | 24.0% | 19.0% | 10.0% | - | - |
IPCALAB Share Price Trend — 1-Year Movement Across Quarterly Results
IPCA Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore IPCA Laboratories share price performance to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
IPCALAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
IPCA Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores